Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q4 FY2022 Earnings Presentation
23 slides from Lincoln Pharmaceuticals's earnings presentation, 2022
Slide 1: Q4 & FY22 Earnings Presentation
Q4 & FY22 Earnings Presentation GROWING IS COMMITMENT. WE POSSESS. P H A R M A C E U T IC A L S LT D . H E ALTH C A R E F O R A L L www.lincolnpharma.com 1
Slide 2: Safe Harbor
Safe Harbor This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Lincoln Pharmaceuticals’ future business developments and economic perfo
Slide 3: Corporate Overview
CORPORATE OVERVIEW BACKGROUND PRODUCT PORTFOLIO MANUFACTURING EXPORTS • Established in the year 1979, • 1700 registered products and • Manufacturing facility at • Exports increased to 56% in Lincoln Pharma has developed another 700 in pipeline Khatraj in Ahmedabad and FY22 from 11% in FY13. 600 plus
Slide 4: FY22 Business Performance & Future Roadmap
FY22 Business Performance & Future Roadmap • Company has reported its Best-Ever Results in a Financial Year with highest Revenue, EBITDA and Net Profit reported on a yearly basis. Company has recommended 15% dividend - Rs. 1.50 per share for FY21-22. Company has achieved strong liquidity position su
Slide 5: FY22 Standalone Results
FY22 Standalone Results NET REVENUE EBITDA NET PROFIT 472.08 69.36 105.47 11.63% 11.41% 13.67% 422.91 62.25 92.78 FY21 FY22 FY21 FY22 FY21 FY22 Q4 FY2022 Earnings Presentation Fig (Rs. Cr) 5
Slide 6: Performance – Focused Therapeutic Areas
Performance – Focused Therapeutic Areas Revenue Breakup 23.2% 4% 2% 3% 2% General Anti Infectives 24.2% 20.5% 9% 24% 29.6% Therapeutic Area Respiratory Systems 1.2% 14% Alimentary Tract and Metabolism Genito Urinary System and Sex Hormones 2.4% Q4 FY22 4.6% Q4 FY21 8.7% 13% 15% Musculo-Skeletal Syst
Slide 7: Performance Overview
Performance Overview Standalone Financial Performance (Rs. Cr) 12 Months Y-o-Y Particulars FY 22 FY 21 Growth (%) Net Revenue 472.08 422.91 11.63% EBITDA 105.47 92.78 13.67% Margin (%) 22.34% 21.94% Profit Before Tax 95.93 83.67 14.65% Margin (%) 20.32% 19.78% Profit After Tax 69.36 62.25 11.41% Mar
Slide 8: About - Lincoln Pharmaceuticals Ltd
About - Lincoln Pharmaceuticals Ltd Providing Affordable and Innovative medicines for healthier lives. VISION To spark a universal attempt to uncover cures of diseases by focused and targeted R&D, through forging Strategic alliances both domestically and internationally. MISSION • Focused on deliver
Slide 9: Key Milestones
Key Milestones 1979 1984-85 2000 1996-97 Lincoln was incorporated & Received WHO – GMP for plant / Domestic Market Expansion; commences operations as a Launched IPO & Listed on BSE production unit Covered 80% of India Market Partnership Firm 2015-16 2016-17 2010-11 2017-18 Listed on NSE Launched 3 p
Slide 10: Growth Drivers – Ready for the Next Big Leap
Growth Drivers – Ready for the Next Big Leap • Company acquired a plant in Mehsana (Gujarat) to launch Cephalosporin products and invested Rs. 30 crore in the CAPEX facility including capacity expansion. Entire funding is from internal accruals. Plant is expected to contribute sales of around Rs. 15
Slide 11: Lincoln Pharmaceuticals Ltd - Financial Overview
Lincoln Pharmaceuticals Ltd - Financial Overview Year Revenue EBITDA Net Profit EPS ROCE Share Price FY 22 472.1 105.5 69.4 34.6 21.9% 311 FY 12 175.5 16.9 5.1 3.1 10.0% 25.5 10 Yrs CAGR 10.4% 20.1% 30.0% 27.1% 1190 bps 28.4% Book Value (Per Share) Market Cap (Rs. Cr) Net Debt (Rs. Cr) 216 623 188 1
Slide 12: Business Revenue Mix
Business Revenue Mix Particular (Rs. cr) FY 2013 (%) FY 2017 (%) FY 2022 (%) Domestic Sales 145.03 74.5% 246.46 67.4% 205.90 43.6% Exports 49.67 25.5% 119.27 32.6% 266.18 56.4% FY13 FY17 FY22 25.5% 32.6% 43.6% 56.4% 67.4% 74.5% Exports Domestic Exports Domestic Exports Domestic Q4 FY2022 Earnings Pr
Slide 13: Global Footprint
Global Footprint Presence over 60 + Countries in Europe, Latin America, Africa, Asia Pacific, South East Asia and 26 States across India Europe: France South & Central Africa: Angola, Benin, Botswana, Asia : Afghanistan, Armenia, America : Bolivia, Burkina Faso, Burundi, Cameroon, Azerbaijan, Bhutan
Slide 14: Research & Development
Research & Development NDDS Formulations Introduced as First Time in India ▪ Anti-fungal vaginal spray ▪ Diclofenac rectal spray ▪ Sildenafil oral spray ▪ Ondansetron Hydrochloride Oral Spray (DOMI-UP) ▪ Paracetamol 1000mg Programmed Release Tablet (PA-12) ▪ Micronized Progesterone Vaginal Spray (PR
Slide 15: Innovations - Lincoln Pharma
Innovations - Lincoln Pharma Q4 FY2022 Earnings Presentation 15
Slide 16: New Launches – Domestic Market
New Launches – Domestic Market Q4 FY2022 Earnings Presentation 16
Slide 17: New Launches – International Market
New Launches – International Market Q4 FY2022 Earnings Presentation 17
Slide 18: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough & Cold / Gyneacological Sterile Ophthalmic Dermatologist Gastro Intestinal Anti Allergic / Anti- Eye Preparation Products Range asthmatics Drops/Ointment Anti-bacterial / Vitamins / Minerals Analgesic / Anti- Anti-malarial Anti-viral/ Anti- Otology / Anti-
Slide 19: Best in Class Facilities
Best in Class Facilities Certifications: EU-GMP, TGA, WHO-GMP Certified; ISO 9001:2015 Certified. R&D Center: Approved by Government of India; Team of 30 plus scientists for R&D. Green Energy: Windmill project and 1MW Solar Roof installed. Producing 65% of company’s total energy consumption. Dosage
Slide 20: Financial Highlights
Financial Highlights (Rs. Cr) Revenue Net Profit 472.1 422.9 69.4 385.2 62.3 51.5 FY20 FY21 FY22 FY20 FY21 FY22 EBITDA Net Worth 105.5 432.9 92.8 366.4 76.5 304.1 FY20 FY21 FY22 FY20 FY21 FY22 Q4 FY2022 Earnings Presentation 20
Slide 21: Profitability Ratios
Profitability Ratios EBITDA Margin PAT Margin 21.9% 22.3% 14.7% 14.7% 19.9% 13.4% FY20 FY21 FY22 FY20 FY21 FY22 ROCE RONW 22.0% 22.6% 21.9% 16.9% 17.0% 16.0% FY20 FY21 FY22 FY20 FY21 FY22 Q4 FY2022 Earnings Presentation 21
Slide 22: Shareholding Information
Shareholding Information March 2022 March 2021 Investor Category No. of No. of Shares % Holding No. of No. of Shares % Holding Shareholders Held Shareholders Held Promoter Group 29 84,22,173 42.05% 30 74,51,904 37.26% Public Holding 32,418 1,16,07,555 57.95% 21,385 1,25,48,096 62.74% Total 32,447 2,
Slide 23: Corporate Office
CORPORATE OFFICE LINCOLN HOUSE B/h, Satyam Complex, Science City Road, Sola, Ahmedabad – 380 060, Gujarat, INDIA Phone: +91-79-41078000 Fax: +91-79-41078062 E-mail: info@lincolnpharma.com Web: www.lincolnpharma.com CIN: L24230GJ1995PLC024288 Darshit A. Shah Gopal Modi CFO, Lincoln Pharmaceuticals Lt
Lincoln Pharmaceuticals — Q4 FY2022 Earnings Presentation on 6ix